Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Verinurad in Japanese patients with gout or asymptomatic hyperuricemia
NCT02078219Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Jan 2014
- Primary completion
- Mar 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of verinurad in gout and hyperuricemia (5 arms), sponsored by AstraZeneca. Primary endpoint: Percent Change in Serum Uric Acid Levels From Baseline at 16 weeks. Started Jan 2014; status: completed.
02
Drugs
verinurad
03
Conditions
gouthyperuricemia
Beyond the preview
Go deeper on NCT02078219.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02078219.